Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash from Investing Activities (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Cash from Investing Activities for 10 consecutive years, with $30.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities rose 43.44% to $30.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$137.2 million, a 184.71% decrease, with the full-year FY2025 number at -$137.2 million, down 184.71% from a year prior.
  • Cash from Investing Activities was $30.3 million for Q4 2025 at Rhythm Pharmaceuticals, up from -$246.3 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $72.5 million in Q1 2022 to a low of -$246.3 million in Q3 2025.
  • A 5-year average of -$11.3 million and a median of $19.8 million in 2023 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: crashed 662.57% in 2022, then soared 731.1% in 2025.
  • Rhythm Pharmaceuticals' Cash from Investing Activities stood at $7.2 million in 2021, then plummeted by 662.57% to -$40.8 million in 2022, then surged by 155.52% to $22.6 million in 2023, then dropped by 6.55% to $21.2 million in 2024, then soared by 43.44% to $30.3 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Cash from Investing Activities are $30.3 million (Q4 2025), -$246.3 million (Q3 2025), and $54.0 million (Q2 2025).